Core Insights - The ENSURE II study results have been published in the peer-reviewed journal Nature Medicine, evaluating the efficacy and safety of the siRNA drug elebsiran in combination with PEG-IFNα for chronic hepatitis B treatment [1][2] - The study also explores the potential role of the therapeutic vaccine BRII-179 in enhancing immune response and increasing HBsAg clearance rates in patients [1] Group 1 - The ENSURE study was conducted in two parts, with the first part involving chronic HBV patients who had not previously received BRII-179, randomized to receive either 48 weeks of PEG-IFNα monotherapy or combination therapy with elebsiran [2] - In the second part, participants who had previously completed a study with elebsiran and BRII-179 were classified based on their anti-HBs peak levels and received 48 weeks of elebsiran combined with weekly PEG-IFNα treatment [2] Group 2 - Professor Jia Jidong, the lead investigator of the ENSURE study, emphasized the study's aim to provide scientific evidence for curative therapies for chronic hepatitis B and address key scientific questions [3] - Encouragingly, the 24-week follow-up data aligned with the results at the end of treatment, supporting the additional clinical benefits of elebsiran and indicating the potential new role of BRII-179 in activating the immune response in chronic HBV patients [3]
腾盛博药-B(02137)：在《自然•医学》发表ENSURE II期研究结果